|
Malignant neoplasm of pancreas
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of pancreas
|
0.800 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic cancer is seen in some breast cancer families with BRCA1 and BRCA2 mutations.
|
12670518 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
BRCA2 is an FA gene and additionally conveys an inherited risk for breast, ovarian, and pancreatic cancer for individuals carrying a single mutated allele [N. G. Howlett et al., Science (Wash. DC), 297: 606-609, 2002].
|
12750283 |
2003 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer.
|
16243825 |
2005 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutations in MSH2/MLH1-mutant CRCs included 75 unique mutations not known to occur in breast or pancreatic cancer per COSMIC v73.
|
28591715 |
2017 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A clinical database review (2000-2009) identified 211 Ashkenazi Jewish (AJ) BC probands who 1) underwent BRCA1/2 mutation analysis by full gene sequencing or directed testing for Ashkenazi founder mutations (BRCA1: 185delAG and 5382insC; BRCA2: 6174delT) and 2) had a FH of PC in a first-, second-, or third-degree relative.
|
21598239 |
2012 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A number of the genes responsible for the aggregation of pancreatic cancer in families have been discovered, including BRCA2, p16/CDKN2A, STK11 and PRSS1.
|
19072437 |
2007 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Additionally, mean ages of diagnosis of pancreatic cancer in BRCA1/2 families differ significantly from the SEER mean (P = 0.0014 for BRCA1 and P = 0.011 for BRCA2 by unpaired t-test).
|
18855126 |
2009 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Biallelic BRCA2-mutations can cause Fanconi anemia and are found in approximately 7% of pancreatic cancers.
|
15277238 |
2004 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
|
24737347 |
2014 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
CTD_human |
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
|
26098869 |
2015 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05).
|
29922827 |
2018 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
|
29441441 |
2018 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
CTD_human |
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
|
21613821 |
2011 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.
|
21750719 |
2011 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Consequently, inherited mutations in BRCA2 are associated with an increased risk of breast, ovarian and pancreatic cancers.
|
27530658 |
2016 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
|
30407790 |
2018 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Especially in male BRCA2 mutation carriers under age 65 prostate and pancreatic cancer risks are increased.
|
18657973 |
2008 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Five BRCA2 truncating mutations were identified, three in families with two or more first- and second-degree relatives with pancreatic cancer.
|
17301269 |
2007 |
|
Malignant neoplasm of pancreas
|
0.800 |
Biomarker
|
disease |
BEFREE |
Germ-line mutations in PALB2 lead to a familial predisposition to breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2 performs its tumor suppressor role, at least in part, by supporting homologous recombination-type double strand break repair (HR-DSBR) through physical interactions with BRCA1, BRCA2, and RAD51.
|
23657012 |
2013 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Germline BRCA2 mutations predispose to the development of pancreatic cancer.
|
15806175 |
2005 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Germline BRCA2 mutations predispose to ovarian, breast and pancreatic cancer, while a germline MRE11 mutation is associated with an ataxia telangiectasia-like disorder.
|
16417627 |
2006 |
|
Malignant neoplasm of pancreas
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in BRCA2 have been shown to predispose to both breast and pancreatic cancer, germline mutations in p16 to melanoma and pancreatic cancer (the FAMMM syndrome), and genetic mutations in STK11/LKB1 to pancreatic cancer in patients with the Peutz-Jeghers Syndrome (PJS).
|
10436789 |
1999 |